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Patients with rare and complex diseases such as congenital adrenal hyperplasia (CAH) often receive fragmented and
inadequate care unless eﬀorts are coordinated among providers. Translating the concepts of the medical home and
comprehensive health care for individuals with CAH oﬀers many benefits for the aﬀected individuals and their families.
This manuscript represents the recommendations of a 1.5 day meeting held in September 2009 to discuss the ideal goals
for comprehensive care centers for newborns, infants, children, adolescents, and adults with CAH. Participants included
pediatric endocrinologists, internal medicine and reproductive endocrinologists, pediatric urologists, pediatric surgeons,
psychologists, and pediatric endocrine nurse educators. One unique aspect of this meeting was the active participation of
individuals personally aﬀected by CAH as patients or parents of patients. Representatives of Health Research and Services
Administration (HRSA), New York-Mid-Atlantic Consortium for Genetics and Newborn Screening Services (NYMAC), and
National Newborn Screening and Genetics Resource Center (NNSGRC) also participated. Thus, this document should serve
as a “roadmap” for the development phases of comprehensive care centers (CCC) for individuals and families aﬀected by
CAH.
1. Introduction
Patients with rare and complex diseases often receive frag-
mented and inadequate care unless eﬀorts are coordi-
nated among providers. For some diseases such as cancer
and cystic fibrosis, the development of comprehensive
care centers (CCCs) has dramatically improved outcomes
and quality of life [1]. In conceptualizing CCCs for the
treatment of congenital adrenal hyperplasia (CAH) the
Congenital Adrenal hyperplasia Research, Education, and
Support (CARES) Foundation, Inc., organized a conference
attended by pediatric endocrinologists, medical endocri-
nologists, reproductive endocrinologists, pediatric urolo-
gists/surgeons, endocrine nurses, psychologists, and con-
sumers (aﬀected individuals and their family members).
The goal of the conference was to discuss creation of an
environment focused on health and quality of life for patients
with CAH and their families [2]. The diverse backgrounds of
the participants were fundamental to the planning process
and influenced the idealized design of these centers.
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2. Components of a Comprehensive Care Center
2.1. Setting. A CCC will be most often located in an
academic-oriented tertiary-care hospital and consists of
multiple healthcare providers in close geographic proximity
to enable easy access for patients and their families. These
healthcare providers should be united in their common
interest and expertise in CAH. Research, training, and
advocacy should be inherent parts of the CCC, and the
CCCs will be in an ideal position to collect outcomes data
to improve patient care and to support research (Table 1).
2.2. Intake/Entry to System. Community health care pro-
viders and state newborn screening programs should be
able to make referrals to the CCC [3]. Establishment of
eﬀective and eﬃcient active lines of communication with
local hospitals, state newborn screening programs, and
regional Primary Care Practitioners (PCPs) should facilitate
referrals and longitudinal care. A single intake point through
a clinical care coordinator should be established and
advertised. Generally, this will be the telephone number for a
designated person in the pediatric endocrine oﬃce, who can
triage calls to the appropriate provider(s). Timely followup
is critical for CAH because this disorder can be rapidly fatal.
Infants strongly suspected of having CAH should be seen and
treated within 24 hours of identification and/or notification.
A hotline or pager should be established for emergencies.
PCPs should be made aware of the availability of tertiary
referral to CCCs for conclusive diagnostic studies and
management of children with CAH due to 21-hydroxylase
deficiency (21OHD) detected through newborn screening.
PCPs should also be aware that newborn screening may
fail to identify some infants with simple-virilizing and
nonclassical forms of CAH and does not seek to identify
forms of CAH other than 21OHD.
The first visit will likely involve the pediatric en-
docrinologist, pediatric endocrine staﬀ, and pediatric
urologist/pediatric surgeon. CCCs should make every eﬀort
to schedule patients for visits with multiple health care
providers on the same day to accommodate families coming
from long distances and tominimize loss of time from school
or work (i.e., pediatric endocrinology and pediatric urology,
medical endocrinology and gynecology, education sessions,
etc.). Attempts should be made to concentrate subsequent
followup visits of several CAH patients on the same day and
to facilitate the peer support process for patients and their
families without compromising confidentiality. Paperwork
details at entry into the system should include completion
of forms that may be required to share health information
with parents and emergency notifications in compliance
with the Health Insurance Portability and Accountability Act
(HIPAA) and making sure that patients have medical alert
identification, such as wallet card and/or jewelry.
2.3. Providers. The CCC should have participation or avail-
ability of an interdisciplinary team, which includes pediatric
endocrinologists, internal medicine endocrinologists, re-
productive endocrinologists, pediatric urologists/pediatric
surgeons, gynecologists, geneticists/genetic counselors, be-
havioral health professionals, nutritionists, social workers,
pediatric endocrine teaching nurses, and nursing staﬀ. To
provide continuity of care, each family should identify a
specific physician as the primary physician for their child.
The care coordinator and educator functions should be
distributed among the available nursing and administrative
personnel. As nurses in the CCC acquire expertise, they
should assume progressively greater responsibility for
education of patients and their families. Adolescents and
adults should be provided with educational opportunities as
they assume responsibilities for their own care. Social work
and translation services should be available and centralized if
possible. In addition to the previously mentioned providers,
access to providers specialized in treating the various
medical, surgical, cosmetic, and psychological consequences
encountered during the long-term care of adult women and
men with CAH should be available.
2.4. Behavioral Health Counseling. Behavioral health special-
ists are key members of the assessment and treatment team;
behavioral health services should be viewed as a component
of routine care. Access to CARES Foundation, Inc. and
other support and educational resources should be provided.
CCCs should facilitate local support group meetings. Both
pediatric and adult behavioral health specialists should
be identified for complex problems beyond basic support
and problem solving. Given the shortage of such trained
professionals, webcasting, or telemedicine among CCCs may
be helpful to provide skilled behavioral health assessment
and care plans for diﬃcult cases.
2.5. Delivering Patient and Family Education. Patient and
family education should be a central focus of the CCC.
Trained nurses, physician extenders (nurse practitioners and
physician assistants), and nurse educators can help educate
patients about the details of CAH and their medications.
They should help parents plan for school, summer camp,
college, and transition to adult care providers. Parents
should be informed about health promotion and disease
prevention and be trained in the emergency use of injectable
glucocorticoids. The educator should also help coordinate
services with subspecialists and secondary healthcare
providers within the team.
A nonphysician caregiver who has an ongoing relation-
ship with a CAH patient can eﬀectively and simultaneously
act as a patient advocate and play an important role in
guiding the patient through transitions from infancy to adult
care. At times, nurses, nurse practitioners, fellows, and physi-
cian assistants may be more accessible to the patient than the
physicians. Patients may share additional information which
they feel uncomfortable telling the physician; that is, they
have not been consistently taking their medications or that
they have added an herbal supplement to their regimen.
When scheduling the first visit, families of a newborn
with CAH should be advised that the initial encounter
will likely involve an extended visit, which includes a
comprehensive educational experience. This visit is often
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Table 1: Measuring success.
Potential medical outcomes:
(i) Quality-of-life using validated surveys
(ii) Biochemical control of CAH
(iii) Symptomatic control of androgen excess (hair loss, acne, hirsutism, amenorrhea, etc.)
(iv) Compliance
(v) Adult height
(vi) Frequency of adrenal crises/hospitalizations
(vii) Reproductive function
(viii) Comorbidities (obesity, hypertension, metabolic syndrome, hirsutism/polycystic ovarian syndrome [women], testicular adrenal
rests [men], and myelolipomas)
Potential surgical outcomes (women):
(i) Number and types of surgeries
(ii) Complications (vaginal stenosis, urinary symptoms, urinary tract infections, etc.)
(iii) Functional and cosmetic results
(iv) Patient satisfaction
(v) Menstrual regularity, fertility
Potential behavioral health/psychosexual outcomes:
(i) Patient and family adjustment
(ii) Psychopathology (depression, anxiety, obsessive-compulsive disorder, eating disorders, substance abuse, etc.)
(iii) Sexual function
(iv) Gender identity
overwhelming because of the vast amount of information
presented. The immediate survival needs, such as gluco-
corticoid and mineralocorticoid replacement therapy and
management of adrenal crises, should be covered first.
A pamphlet including links to informative websites (i.e.,
CARES Foundation, Inc., http://www.caresfoundation.org/,
other helpful support groups, CAH message boards and
other appropriate online and organizational resources;
professional organizations including The Endocrine Soci-
ety, http://www.endo-society.org/, Pediatric Endocrine Soci-
ety (formerly Lawson Wilkins Pediatric Endocrine Soci-
ety), http://www.lwpes.org/, European Society for Pediatric
Endocrinology, http://www.eurospe.org/). Preprinted forms
and handouts for common procedures should be provided to
the family. More advanced topics and future issues should be
introduced and expanded at subsequent visits. At each visit,
the mechanism to access the emergency system should be
reviewed with parents and patients. As the child grows and
develops, the CCC should provide a resource for education
and discussion of additional topics such as riding the school
bus for kindergarten, school trips, sexuality, fertility, and
many other concerns (see below).
2.6. Patient Confidentiality. The CCCs require a flexible
environment for the sharing of pertinent information
among providers. In all situations, the patient’s rights and
privacy are paramount. All personnel should be trained in
HIPAA procedures and reminded to respect patient rights
at all times. While training and research opportunities are
readily available, these activities are not excuses for breaches
in confidentiality of any sort. Communications should
contain only information relevant to the situation at hand.
Photographs should only be taken when medically necessary
and should not be taken or distributed for teaching and
research purposes without written informed consent and
deidentification. The practice of having large numbers of
individuals examine a patient’s genitalia should be avoided.
Exposure to sensitive aspects of the physical examination
should be limited to essential providers and to members of
the team of support personnel and trainees.
The Genetic Information Non-Disclosure Act of 2009
(GINA) includes penalties for breaches in confidentiality.
The ARRA/HITECH Act of 2009 (the recovery act) strength-
ens HIPAA provisions by extending the application of HIPAA
to personal health records and also by creating requirements
for notification of patients about potential breaches in con-
fidentiality. These legislative mandates strengthening confi-
dentiality protections are particularly important given the
increased use of electronic health records and information
exchange. Patient preferences, patient choices, and the level
of patient knowledge, including information shared with
adolescent patients, should be included in electronic medical
summaries as a means of promoting patient-centered care.
Future data repositories should be designed with strong
provisions for controlling and monitoring disclosure of
personal identifiers, genetic analyses, diagnoses, and other
confidential information.
2.7. Communication. Communication between the physi-
cians and ancillary staﬀ of the CCC with referral practices
in the region is essential for continuity of patient care. CCCs
are encouraged to develop pamphlets on CAH for PCPs and
other medical providers, and a copy of the pamphlet on
the type of CAH involved should be included in the initial
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communication.Medical summaries are essential to facilitate
communication between multiple providers. Centers should
maintain lists of PCPs such as pediatricians, family practi-
tioners, internists, and gynecologists who are comfortable
with the care of patients with CAH and are sensitive to the
particular needs and vulnerability of these individuals. Cur-
rent lists of local subspecialists, such as orthopedic surgeons,
otolaryngologists, ophthalmologists, and so forth, should
also be maintained by the CCC. PCPs should receive a letter
after each visit to the CCC, typically from the lead provider.
This letter should summarize the patient’s current status,
management plan, the most pressing problems addressed in
the interval between appointments, and any additional areas
of concern. A copy of the note or an abstracted summarymay
be sent to the patient (or parents of minors). The patient and
family need to sign a release of information form to enable
the CCC providers to communicate with the PCP and other
providers, particularly for emergency situations.
CCCs are also encouraged to explore the use of com-
munication technologies to improve patient care, particu-
larly for patients living far from the center. Infrastructure
should be developed to utilize telemedicine, web-based
communication systems, and portable data organizers. A
CCC website should be available that includes information
specific to that center (locations, events calendar, and tele-
phone/fax numbers), links to other relevant sites, and infor-
mation about ongoing research studies and support group
contacts.
2.8. Financial Considerations. Information regarding finan-
cial issues, including insurance forms, prior authorizations,
and statements of medical necessity should be provided to
families that identify mechanisms to alleviate the financial
burden of the healthcare costs associated with CAH. Finan-
cial advisors should be available through the CCC to help
patients and families take advantage of available resources
(such as charity care, State Children’s Health Insurance
Program, Medicaid, pharmaceutical company patient assis-
tance programs, and Catastrophic Illness in Children Relief
Funds), to help families negotiate the complex processes
involved in applying for such services, and to help families
obtain reasonably priced lodging (e.g., Ronald McDonald
Houses) if overnight stays are necessary. The CCCs should
advocate with private and public payers for reimbursement
of necessary services, tests, and treatments, including those
not typically covered, such as psychological counseling,
genetic services, hair removal or hair loss treatments, consul-
tative services by teammembers, and other services provided
to patients outside an oﬃce visit such as counseling the
patient by telephone or email. The CCC coordinator should
be able to streamline testing requested by various teammem-
bers to maximize cost eﬀectiveness. CCCs should explore
negotiations with laboratories for lower test costs based on
economies of scale for steroid assays and genetic tests.
2.9. Infrastructure. Additional activities of the CCC should
include interdisciplinary conferences to discuss specific
patients, medical ethics, transition between providers, and
relevant scientific studies. Paramount to coordination of care
is provider access to records from visits with other providers.
Centers should have defined procedures for obtaining labo-
ratory and radiology data from reliable reference laboratories
and imaging centers, either prior to or on the day of
appointments. Written protocols should exist for generating
requisitions, scheduling blood draws and other studies,
review of results, and communication of recommendations
to patients and families. Nursing staﬀ, secretarial staﬀ, and
patients/parents should be familiar with these protocols.
A single integrated electronic medical record (EMR) is
ideal. In the absence of an EMR, physical, electronic, or
other procedural links between systems may need to be
developed. In some instances, hard copymedical recordsmay
be obtained bymail, fax, or secure electronic communication
from outside physicians.
2.10. Transition. The transition of a child with CAH to an
internal medicine endocrinologist’s care means a fundamen-
tal shift in treatment goals, parent-patient relationships, and
approach to care delivery [4, 5]. Adult patients are solely
responsible for their actions, adherence, and choices; their
parents will participate in these decisions less than during
childhood. Loss of the longstanding relationship with the
pediatric care team can be diﬃcult for the adolescent and
his/her family. One goal of the idealized CCC model is
a smoother transition process by providing an integrated
network during this critical phase. A well thought-out,
individualized, transition plan will ensure that the patient
has a positive experience and is well prepared for life as an
adult with CAH.
Many adult patients will no longer be living in the
same city in which they lived as children. The pediatric
endocrinologist may need to assist the patient in finding
an IM endocrinologist not only in a new medical center,
but also in a new location. The timing of the transfer
will generally occur between the ages of 16 to 21, with
the pediatric endocrinologist, the patient, and the patient’s
family determining the exact time based on the needs and
maturity of the patient. A structured program with written
documents has been shown to be eﬀective in transitioning
pediatric patients to an adult health care provider with other
chronic conditions [6, 7].
3. Goals and Relevant Topics Considered by
Age Group
3.1. Treatment Goals. The clinical management of the patient
with CAH is inherently age and gender specific [8–11]. In
devising regimens for individuals with CAH, the endocrinol-
ogist should first review the treatment goals. Confirmation of
the diagnosis of CAH (and also of the clinical form) may be
necessary using hormonal and/or genetic testing depending
on the pediatric medical information available. The CCC
should develop a structured process for age-appropriate
discussions to educate a patient about his or her disorder, its
treatment, and how to handle emergencies away from home.
Eventually, the patient should be able to describe CAH and
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its potential complications, understand the need for stress
glucocorticoid dosing and the need to wear medical alert
identification jewelry, and know his/her own medications,
dose and schedule. Therapy should be individualized based
on age, gender, prior history, body composition, other ill-
nesses, and immediate goals [12].
Parents often worry about giving 3-4 doses of medication
per day to their children within school and activity schedules.
Many adults perceive that they cannot take divided doses
of hydrocortisone due to work schedules; however, chronic
therapy with longer-acting and more potent synthetic glu-
cocorticoids may increase risks for side eﬀects, including
obesity, glucose intolerance, bone loss, skin fragility, poor
sleep, and immunosuppression. The endocrinologist should
emphasize that individual responses to specific medications
are only somewhat predictable, and trial periods are nec-
essary to assess the benefits and complications of each
regimen. It is recommended that CCCs develop pamphlets
to discuss treatment options. The CCC should be able to
elicit the input of secondary providers, including dietitians,
physical therapists, and personal trainers, to help the patient
manage weight gain and deconditioning that might arise
when therapies are intensified. Although these specialists
need not be a part of the CCC, specific individuals in the
region should be identified and also educated about CAH to
provide better care.
3.2. Timing of Changes. Significant regimen changes should
be avoided during times of major life changes, such as start-
ing school, moving, going away to college, gettingmarried, or
starting a new job. These changes should begin several weeks
prior to or started several weeks after the event transpires. For
adolescents and adults, many of these events are associated
with weight gain, fatigue, poor sleep, and emotional changes;
consequently, these symptoms might be erroneously
attributed to the new treatments if not separated in time.
While laboratory monitoring is important, clinical responses
are paramount, and overtreatment simply to have laboratory
values in the normal range is strongly discouraged.
3.3. The Newborn. As discussed above, infants should be
referred to the CCC by PCPs or by newborn screening
programs. Goals include confirmation of the diagnosis
of CAH, initiation of hormone replacement therapy, and
family education. In addition to pediatric endocrinologists,
pediatric urologists/surgeons, endocrine nurse educators,
and behavioral health specialists may be involved. The initial
visits should form the basis for long-term relationships
between the family and the CCC.
3.4. The Child. Every clinic visit for a child or adolescent with
CAH should include a comprehensive endocrine evaluation
and an assessment/screening of behavioral health status.
Involvement of the child in this conversation, as appropriate
for his/her level of maturity, is important to educate the
child about why he/she takes daily medications and may
occasionally need to miss school for doctors’ appointments.
Medical issues addressed should include adequacy of
hormone replacement therapies, adherence to treatment
recommendations, evaluation of growth and pubertal status,
evaluation for excessive androgen secretion, reinforcement
of appropriate stress glucocorticoid coverage, and use of
medical alert identification. Hormone determinations and
radiographic testing should be performed as necessary to
assess adequacy of hormone replacement therapy. From the
time of diagnosis, sharing of information with the child
with CAH should be planned with the parents through
an ongoing dialogue regarding what is developmentally
appropriate for the child [13]. Medical education and
counseling for children is a continuous process, gradually
increasing in sophistication, in which teaching occurs at a
level that is commensurate with the progressing cognitive
and psychological development of the child, with specific
emphasis on fostering open parent-child communication
[14]. Thus, open and honest communication with the patient
and the family is essential. Behavioral health assessment
ideally consists of a brief interview conducted separately with
both patient and parents by a qualified behavioral health
provider.
3.5. The Adolescent. Although the pediatric endocrinologist
will continue to be the dominant care provider during
adolescence, the adolescent must develop an understanding
of his or her condition. The pediatric endocrinology team
has the responsibility for educating the child and the parents
about the child’s impending independence. Discussions
about puberty should be initiated at the appropriate age
for each child as they develop, with discussion of privacy
and appropriate boundaries. Transitioning the adolescent
patient into adult care should be gradual process that begins
years prior to the change in health care providers [15]. This
process should include provision of medical records which
include information on the type of CAH, genetic reports
(if mutation(s) is/are known), age of diagnosis, current and
significant past treatment regimens (including rationales
for deviation from typical therapies), genital and gonadal
surgeries, other medical problems and surgeries, family and
social history, allergies, psychological issues (if any), and
recent laboratory data. A summary paragraph capturing the
patient’s essential characteristics, treatment, and particular
needs should conclude the transfer form or referral letter.
Joint meetings between the adult and pediatric health care
providers are ideal, but some centers may be structured such
that the patient will see the endocrinologist in a diﬀerent
physical location and/or at a diﬀerent hospital.
During the middle school and high school years, age-
appropriate education should occur with and without the
parent present, and should foster independent knowledge
and eventual self-management. Patients should be encour-
aged to ask questions during each oﬃce visit. Independent
health care behaviors should begin to develop in the
pediatric setting. Parents must be educated about how to
give the child increasing responsibility for his/her healthcare.
Adolescents should be provided with time alone with the
physician(s) without the parent(s) in the exam room. The
adolescent needs to be oﬀered the opportunity to discuss
personal issues such as menstruation, contraception, fertility,
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gender identity concerns, and use of tobacco, alcohol, and
recreational drugs in the absence of their parents.
Subjects covered during the transition from pediatric
to adult care providers should include planning for health
care insurance coverage/governmental health plan for the
child after age 18 years or after college. Additional topics
include sexual, urological, and reproductive health includ-
ing contraceptive counseling, genetic counseling, mental
health issues, body weight concerns, and understanding
the genetics of CAH. Pertinent discussions should include
how to stay healthy in college or other after high school
situations, potential alcohol/recreational drug abuse, healthy
eating, and weight-gain avoidance. Discussions about how
to handle illnesses and emergencies should be held. Specific
plans should include telling a roommate about CAH and
the potential need for glucocorticoid injections, knowing
locations of college health center facilities and the local
emergency department, and knowledge of insurance infor-
mation. Additional topics for the college-bound adolescent
include how to handle homesickness, stress, anxiety, and
depression, and how to care for mental health. Emphasizing
the profound cosmetic and reproductive side eﬀects of
nonadherence with medications and monitoring can often
have a bigger impact for teens than merely emphasizing
the health aspects of noncompliance. Young adults should
be prepared with more knowledge about CAH than their
new healthcare providers in college health/armed forces
health services [17]. Thus, they need to learn to advocate
for themselves in the healthcare setting and learn how to
explain CAH and their health needs to new healthcare
providers.
Adolescent girls need to understand their history, if
any, regarding ambiguous genitalia at birth and the extent
of surgery. Issues related to sexuality, sexual function, and
genital anatomy including the use of vaginal dilators versus
surgical options may warrant discussion. When appropriate,
this discussion should include how to responsibly approach
sexual activity, talking to a sexual partner about genital
reconstruction, and preparing for the first sexual experi-
ence. Family discussions should be encouraged and some
education should occur prior to gynecology referrals. Care-
givers should be sensitive to cultural diﬀerences in relating
information. They must educate parents about adverse long-
term psychological consequences of withholding medical
information if parents are resistant to such discussions.
CAH nurse educators should reinforce educational content,
review anatomy, teach the use of vaginal dilators, and
answer questions related to and in conjunction with the first
gynecologic visit. They should help the patient determine
questions and goals related to such visits. Some women with
CAH may have the false impression that pregnancy will not
be possible. Since many women with CAH have trouble
conceiving, they should be aware that pregnancy may take
longer to achieve and should have this information available
for family planning. They should also know that CAH is not
an eﬀective form of birth control and be informed about
the types of contraception available. Counseling women
about prevention of sexually transmitted infections and
HPV vaccination should be included in their gynecological
care.
3.6. The Adult Female. Adult females also require periodic
assessments of the adequacy of glucocorticoid replacement,
the possible development of myelolipomas, bone health,
and reproductive function. There is also a need to address
genetic counseling concerns, update health education, and
assess health maintenance activities [18]. Women with
nonclassical CAH (NCAH) often come to medical attention
for infertility, oligoanovulation, and hirsutism; treatment
should be directed to these needs [19]. The degree of
androgen excess inNCAH varies, and CCC physicians should
not underestimate the need for, or complexity of, treatment.
The same goal-directed principles guiding therapies apply as
for women with classical CAH. The care of the adult female
is further complicated by additional needs for gynecological
care and, in some instances, obstetrical care. Specialized
behavioral health care may be required to assist the patient
in discussing issues that might be unique to CAH, especially
sexuality and gender identity. The adult female should be
assured that although her care may be complex, the CCC has
suﬃcient expertise in all relevant areas. Adult females should
also receive routine screening and healthmaintenance testing
(Pap smears and mammograms).
Each CCC should have an available gynecologist (or
another caregiver trained in gynecological exams and issues)
who is knowledgeable about CAH to both examine and dis-
cuss issues with CAH females. Pap smears are recommended
by the American College of Obstetricians and Gynecologists
by age 21 or within 3 years of sexual intercourse [20]. Having
a health care provider who is comfortable discussing sexual-
ity and has a relationship with the patient is extremely impor-
tant. A comfortable patient-physician relationship will facil-
itate discussion of feelings about genital appearance and/or
sexual and/or reproductive functioning. A solid relationship
will also foster involvement of additional health providers,
including psychosexual specialists and sex therapists, gyne-
cological and/or urological specialists, and/or reproductive
endocrinologists. Many females may begin seeing a gyne-
cologist prior to or along with seeing an internal medicine
endocrinologist, depending on the individual patient’s
needs.
For women with classical CAH, treatment regimens
will vary with their reproductive needs and sensitivity to
androgens and progesterone. For women who do not want
to become pregnant, nonglucocorticoid therapies should
be discussed and oﬀered to minimize exposure to sup-
raphysiological doses of glucocorticoids. These adjunctive
measures include antiandrogens, oral and transdermal con-
traceptives, intrauterine devices, and topical or mechanical
depilation methods. The CCC should provide mechanisms
or forums to review and to optimize individual patient
treatment plans with the endocrinologist, gynecologist, and
other relevant providers in a case-review format [21].
Most importantly, the endocrinologist should emphasize
that a woman is not locked into a single regimen for life,
and alterations are often desirable as the needs and goals
change.
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3.7. Pregnancy Considerations. Women with both classical
and NCAH desiring pregnancy should be oﬀered precon-
ception counseling prior to pregnancy. This counseling
may include genetic counseling and testing the partner
(when appropriate), discussing the likelihood of dose titra-
tion during pregnancy, the increased need for Caesarian
section in classical patients, and the use of stress-dose
glucocorticoids during labor and delivery. A reproduc-
tive endocrinologist should assess the need for fertility
treatment. A team approach to pregnancy, including an
endocrinologist, a reproductive endocrinologist (as needed),
and an obstetrician (maternal-fetal medicine specialist when
indicated), is highly recommended. Discussion regarding
the risk-benefit ratio of prenatal dexamethasone therapy
may be considered, but only in the context of a research
setting, per current Endocrine Society guidelines [22]. The
CCC team plays a key role during pregnancy, during
which time close communication is important between
the endocrinologist and the obstetrician. After becoming
pregnant, women with CAH should be aware that their glu-
cocorticoid and mineralocorticoid doses may change during
gestation.
3.8. The Adolescent and Adult Male. Adult males with CAH
require periodic evaluation to assure adequate glucocorticoid
replacement, monitor for the development of testicular
rests and adrenal myelolipomas, monitor bone health, and
address fertility issues (if desired), and for general health
maintenance. Males with CAH may have concerns about
fertility if they have known adrenal rest tissue. Some may
be under the false assumption that they are unable to father
children and may need to be reminded that CAH is not a
form of birth control. Males who have a history of precocious
puberty may have concerns about the normalcy of their
development. Open discussion and ongoing developmentally
appropriate education is warranted throughout adolescence
and adulthood [23].
For men with classical CAH, moderate doses of hydro-
cortisone or a longer-acting glucocorticoid, along with
fludrocortisone, are generally suﬃcient to prevent adrenal
insuﬃciency, maintain fluid and electrolyte balance, avoid
suppression of gonadotropins, and prevent development of
tumors, such as adrenal rests in the testes and myelolipomas
in the adrenals. Higher doses or more potent glucocorticoids,
as well as the reinforcement of good compliance may be
necessary to induce regression of these tumors and promote
fertility. The CCC should coordinate urological evaluation
(testis size, need for sperm retrieval, etc.) and screening
for complications with treatment changes and monitoring
schemes instituted by the endocrinologist. Men with NCAH
rarely require treatment.
The internal medicine endocrinologist should manage
hormonal therapies and related endocrine issues, and the
PCP should generally handle unrelated and acute problems,
and routine healthmaintenance. Access to genetic counseling
and DNA testing should be readily available for aﬀected
individuals, partners, and other interested family members.
Education of the patient, who may have relied on his parents
to manage his CAH, is an important goal. Patients should
receive age-appropriate routine screening examinations as
coordinated with their PCP (blood pressure, fasting lipids,
and colon and prostate cancer screening). Attention to
conditions exacerbated by chronic glucocorticoid use, for
example, metabolic syndrome, obesity, and osteoporosis,
should be considered.
3.9. Bone Health. Treatment of CAH demands life-long
glucocorticoid replacement. However, finding the “exact”
or “best” dose remains elusive. Undertreatment has been
associated with adrenal insuﬃciency (adrenal crisis) and
androgen excess (virilization and short stature), whereas
overtreatment causes iatrogenic Cushing syndrome with
numerous physical and metabolic consequences. Although
treatment requires supraphysiological dosing compared to
adrenal insuﬃciency of other etiologies (such as Addison’s
disease), excessive dosing beyond that required for good
control of CAH, especially after the newborn period, may
be deleterious to bone health over the lifespan. Further-
more, addition of medications to maximize a child’s height
potential may aﬀect bone mineral density [24–26]. Although
such treatments have positive outcomes (height, self-esteem,
etc.), the risk/benefit with regard to bone health demands
that the CCC be attentive to skeletal integrity and consider
screening during the course of these regimens. Because the
potential risk for osteoporosis remains to be quantified, the
CCC should have the capacity to monitor and treat bone
disease, even in young patients [27].
4. Newborn Screening, Diagnosis, and Genetics
4.1. Initial Newborn Screening. Universal newborn screening
(NBS) for 21OHD identifies both male and female aﬀected
infants, decreases mortality and morbidity from severe elec-
trolyte abnormalities, and may reduce the risk of incorrect
sex assignment in severely virilized females. NBS for CAH
is currently available in all 50 states and in many other
countries. All screening laboratories for CAH are expected
to participate in the NBS quality assurance program [2]. The
state NBS program should be encouraged to recognize the
CCC as the regional referral center for newborns identified
by NBS. The CCC should be familiar with its state NBS
protocol, sample and data collectionmethods, definitions for
screen-negative and screen-positive test results, and detailed
procedures followed for each type of test result.
Blood sampling is usually performed when newborns
are older than 24 h. Most screening programs measure
17-hydroxyprogesterone (17OHP) in blood spots using
time-resolved, dissociation-enhanced lanthanide fluoroim-
munoassay (DELFIA, Perkin Elmer Corporation, Turku,
Finland) or similar assays that are highly automated; how-
ever, this method yields many false positive results due
cross-reactivity with other steroid metabolites. Moreover,
increased serum concentrations of 17OHP are associated
with low birth weight and illness, increasing the incidence
of false positives in premature and sick infants. Adjusting the
cutoﬀ of 17OHP for gestational age instead of birth weight
improves the specificity of the test if available. CAH screening
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at present still has a low predictive value—approximately 1%
in the United States—as a newborn screening protocol [2].
4.2. Second-Tier Newborn Screening. The issues of cross-
reactivity and specificity can be alleviated by the use of liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
methods [28]. This methodology can detect 17OHP as well
as other compounds like androstenedione, 11-deoxycortisol,
21-deoxycortisol, and cortisol. The use of precursor/product
ratios such as (17OHP + 21-deoxycortisol)/cortisol elimi-
nates most of the falsely positive screening results in infants
with elevated 17OHP due to stress, illness, or prematurity.
Using this approach, the positive predictive value of CAH
screening improves significantly to 30%–100%. Therefore,
a second-tier test by LC-MS/MS for all positive screening
results should be considered in all screening laboratories that
have appropriate equipment and trained personnel available
[29], which may be preferably performed at a regional
facility.
4.3. Evaluation of Newborns with Positive Screening Results.
Newborns with moderately elevated 17OHP levels (see
below) are usually followed up with a repeat filter paper
specimen. The PCP usually evaluates infants with higher
17OHP values, using the medical history, a standardized
physical examination, and serum tests for electrolytes and
a serum 17OHP level. If these are abnormal, the infant
should be referred for further evaluation to a specialist.
The gold standard for diagnosis of CAH is a high-dose
cosyntropin (ACTH1−24) stimulation test. Existing normal
values are defined based on stimulation tests employing
a pharmacological dose of 0.125–0.25mg cosyntropin. It
should be kept in mind that 17OHP levels may be elevated in
other enzymatic defects besides 21OHD. To fully diﬀerentiate
among these other disorders aﬀecting steroidogenesis, the
clinician should ideally measure 17OHP, cortisol, deoxycor-
ticosterone, 11-deoxycortisol, and 17-hydroxypregnenolone
30–60 minutes after cosyntropin with at least one measure-
ment each of dehydroepiandrosterone and androstenedione.
If there is a high index of suspicion for CAH (ambiguous
genitalia in females, markedly elevated 17OHP on the NBS
in either sex, and/or electrolyte abnormalities), treatment
should be instituted immediately without waiting for the
results of a cosyntropin stimulation test. Large pediatric
referral hospitals with an on-call pediatric endocrinologist
may be able to conduct such testing quickly; however, the
risks of delaying treatment to perform the test may outweigh
the benefits, particularly in sick infants with abnormal
electrolytes, and markedly elevated ACTH levels. A rapid
fluorescent in situ hybridization (FISH) of interphase nuclei
with Y chromosome probes may be done when indicated
in the diﬀerential diagnosis, as well as a pelvic sonogram
and genitogram in virilized female infants. DNA testing for
characterization of 21OHD (CYP21A2) alleles should be an
option available at the CCC.
4.4. Diagnosis of CAH Beyond the Newborn Period. Patients
suﬀering from classical forms of CAH due to 21-hydroxylase
deficiency can be diagnosed by measuring 17OHP, preferably
in the morning. Concomitant measurement of adrenal
androgens (i.e., dehydroepiandrosterone and androstene-
dione) may identify this and other adrenal causes of
virilization. Patients with NCAH secondary to 21OHD
generally require a cosyntropin stimulation test to confirm
the diagnosis. In general, ACTH-stimulated 17OHP values
greater than 1500 ng/dL are associated with identification of
mutations on both CYP21A2 alleles [30] but vary with the
laboratory used.
4.5. Standards of Hormone Diagnostics. Specific methods
should be used for hormone analyses. LC-MSMS methods
give highest specificity and sensitivity; enzyme immunoas-
says, especially those for aldosterone, have the same lim-
itations for specificity and sensitivity as described above.
Each diagnostic laboratory should establish validated cut-
oﬀ levels for diﬀerent age groups and pubertal stages;
regional or national reference laboratories are preferred.
LC-MS/MS is extremely reproducible; normative data can
be transferred from one laboratory to another if the same
methodology/instrumentation is used. Analysis of urinary
steroid metabolites with GC-MS methodology may also
allow proper diagnosis, but extensive experience is currently
lacking.
4.6. Technical Precautions. Molecular testing for CAH due
to 21OHD faces painstaking technical challenges, such
as the presence of the highly homologous closely linked
pseudogene (CYP21A1P), which serves as the donor for
transfer of deleterious mutations to the normally active
CYP21A2 gene, a process termed gene conversion. There is
also significant variation in gene copy number, and deletions
of CYP21A2 comprise∼20% of alleles. Finally, these genes lie
in the HLA major histocompatibility complex, a region with
unusually high rates of genetic recombination. It is critically
important to ensure that CYP21A2 is specifically amplified
and not contaminated with CYP21A1P sequences, which
otherwise represent a source of false-positives. Prenatal
molecular diagnostics should be repeated after birth for
confirmation.
4.7. Technical Requirements. Whenever possible, genotyping
should be performed simultaneously on samples from the
patient (proband) and both parents. Obtaining samples from
diﬀerent generations is important to “set phase” because
multiple deleterious mutations can occur on one allele.
The applied techniques should be capable of detecting the
most common mutations, which are all gene conversions,
and should reliably determine gene copy number. Full-
length DNA sequencing should be available to character-
ize alleles with private mutations that are not generated
by intergenic recombination. Additionally, if mutations
on both alleles cannot be reliably identified, laborato-
ries should have the capability of performing diagnosis
by determining segregation of alleles using closely linked
variable-number-of-tandem-repeat polymorphisms. Multi-
plex ligation-dependent probe amplification (MLPA) assays
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show promise in helping to resolve ambiguous results from
standard methods.
4.8. General Considerations. CAH is inherited as an auto-
somal recessive trait. Thus, there is a 25% probability that
siblings of the index case will also have CAH, a 50%
probability that they will be asymptomatic carriers, and
a 25% chance of being totally unaﬀected. Based on a
classical CAH incidence of approximately 1 : 16,000–20,000,
the prevalence of carriers in the general population is 1/63–
1/71. If we assume the high-end value of 1/60 potential
partners being heterozygotes for CAH, a patient with classical
CAH will have a 1/120 probability of having a child with
classical CAH. For NCAH, about two thirds of patients
are compound heterozygotes, carrying one allele that causes
classical CAH and one that causes NCAH [31]. The milder
mutation determines the phenotype; hence, the NCAH
parent has a 1/240 risk of having a child with classical CAH.
Recent studies suggest that this risk, rather than being about
0.4%,may actually be closer to 2.5% [32]. Given the relatively
higher prevalence of mild CAH mutations, there is a greater
risk for oﬀspring of a parent with either classical CAH or
NCAH to have NCAH, which is significant but not life
threatening.
4.9. Anticipated Pregnancies. Genetic counseling is valuable
for parents who have had at least one child aﬀected
with CAH and may plan for future children. Additionally,
adults themselves aﬀected with CAH may request counseling
and genotyping for themselves and/or their partner before
planning for children. Genetic counseling can and should
be oﬀered to parents soon after the birth of an aﬀected
child. The genotypes of the proband and parents should
be obtained well before another pregnancy is contemplated.
Patients of reproductive age should also be informed and
encouraged to seek genetic counseling before contemplating
future pregnancies.
4.10. NCAH. NCAH patients should be oﬀered genetic
testing if a pregnancy is desired. As discussed above, 2/3 of
NCAH patients carry one classical CAH allele, yielding a
2.5% risk of giving birth to a child with the classical form
and a 15% risk of having a child with NCAH form [32].
The carrier frequency is high in the general population,
varying from 1 : 60 for those carrying mutations predicting
classical form and 1 : 16 for those carrying the NCAH
mutations, depending on the ethnicity. All spouses of a
patient with NCAH carrying one classical CAH gene should
be encouraged to have genotyping if the couple desires a
pregnancy and would consider prenatal diagnosis and/or
prenatal treatment.
4.11. Delivery of Counseling. Ideally, a well-informed pedi-
atric or adult endocrinologist or endocrine nurse specialist
should deliver introductory genetic counseling and explain
basic concepts at an early stage in the physician-patient
relationship. Verbal discussions should be reinforced with
written materials and/or reference to reliable web-based
information on CAH, genetic testing, prenatal diagnosis
and prenatal treatment [33]. Formal counseling should
subsequently be delivered by a geneticist and/or a genetic
counselor experienced in this area.
4.12. Prenatal Diagnosis and Prenatal Treatment. Well-
informed pediatric/adult/reproductive endocrinologists and
geneticists/genetic counselors experienced and knowl-
edgeable in this area should participate in the discussion
of the available options including “pros” and “cons”.
More detailed information on this topic can be found
in the Endocrine Society Clinical Practice Guidelines on
Congenital Adrenal Hyperplasia (http://www.endo-socie-
ty.org/guidelines/Current-Clinical-Practice-Guidelines.cfm)
[22].
5. Specialized Surgery for
Congenital Adrenal Hyperplasia
The salt-wasting and simple-virilizing forms of CAH are
often accompanied by varying degrees of prenatal mas-
culinization of the female external genitalia as a result of
excessive adrenal androgen production during gestation. In
the female patient with virilizing CAH, excessive androgen
concentrations can cause the clitoris, labia, and vagina to
develop along a more masculine tract. As 95% of children
with CAH have 21OHD, the ensuing discussion, unless
otherwise indicated, will refer to females with this form of
CAH. Although no specific discussion addresses the needs
of undermasculinized males with rarer forms of CAH, it is
acknowledged that these patients have separate yet important
issues.
The development of the ovaries, fallopian tubes, cervix,
upper vagina, and uterus are unaﬀected. Thus, although
girls with CAH can be born with male-appearing external
genitalia, they have normal ovaries and female internal
reproductive organs and retain the potential for fertility.
With optimal medical treatment and, in some girls, surgery
to separate the lower urinary and reproductive tracts, the
potential for fertility is retained, and the issues associated
with the masculinized lower genital tract can be corrected or
alleviated [34].
These masculinizing changes of CAH can result in the
joining of the female urinary and reproductive systems
at the level of the urethra and vagina (referred to as
a urogenital sinus). The higher the level of confluence
of the urethra and vagina, the more likely it is that
the aﬀected individual will have diﬃculties with urinary,
reproductive, and sexual function. These diﬃculties may
include chronic urinary frequency, urinary incontinence,
“spraying” of urine during micturition, inability to use
a tampon, or inability to have penile penetrative sexual
intercourse. In addition, psychological and self-image issues
may also develop. In adolescent and adult patients who
have clitoromegaly, painful sexual arousal may also occur.
Nevertheless, despite moderate degrees of masculinization,
healthy growth and development are possible for aﬀected
girls.
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5.1. Surgical Considerations. In the past 20 years, under-
standing of the anatomy and neuroanatomy of the female
genitalia has expanded greatly. Furthermore, considerable
advances in surgical techniques have emerged, with the aim
of improving the functional, cosmetic, and psychological
results of surgical intervention, including the preservation of
genital sensitivity and orgasmic potential.
5.2. Anatomic Considerations. In females with a urogenital
sinus of any degree, vaginoplasty is required for penetrative
penile intercourse. There are conflicting opinions regarding
the optimal timing of surgery. Management of clitoromegaly
is similarly controversial. For girls with significant genital
virilization (Prader stage 3 or greater), there may be an indi-
cation for early genital surgery (age < 6 months), and these
children should be cared for by a CCC surgeon specifically
experienced with operative management of children with
CAH. Nevertheless, some families may elect not to undertake
early surgery for various medical, ethical, or cultural reasons.
Such families should be supported in their decision.
5.3. Decision Making. The psychosocial and cultural issues
relating to early versus late genital surgery have been poorly
addressed, yet they play a major role in the surgical decision-
making process. The factors that guide parents’ decisions
regarding whether to subject their infant daughter to surgical
intervention of the lower urogenital tract are complex. Such
factors include: (1) the likelihood that medical issues, such as
urinary tract infections and urinary incontinence secondary
to vaginal voiding, will ensue, (2) parental desire for early
“normalization” of external genitalia, (3) parental desire to
have surgery performed early to prevent the child’s memory
of surgery versus parental desire to have the individual
partake in the decision-making process, and (4) degree of
masculinization of the external genitalia.
5.4. Risks and Benefits. Although surgeons constantly strive
to improve their techniques, genital surgery may not be
without complications or long-term sequelae. As such, health
professionals involved in the care of children with CAH
recommend that masculinized girls be evaluated early in
life and that parents have a thorough understanding of
the options, risks, and benefits of surgical intervention, so
that they can understand all of the choices available for
their child. This should include the option of no surgery
at all, no clitoral surgery, and the relative advantages and
disadvantages of early (perinatal) versus later (postpubertal)
surgical intervention. Consideration should be given to
development of a standardized informed consent document
describing the risks and benefits of early versus later
surgery. Furthermore, considerations to comply with the
2002 Consensus Statement on 21OHD from the Pediatric
Endocrine Society and the European Society for Pediatric
Endocrinology [35], as well as the 2010 Endocrine Society
Guidelines [22], should be included in this discussion.
5.5. Adults. The issues and needs of adult women with
CAH are poorly understood, as limited long-term followup
data are available. This is particularly true when comparing
long-term results between early and delayed genital surgery.
Residual problems with sexual and/or urinary function
following surgery may be significant. Some adolescents
and adult women who underwent urogenital sinus surgery
may develop stenosis of the vaginal introitus. As a result,
voiding may be diﬃcult, and the use of a tampon or
sexual intercourse may be painful or impossible. In these
situations, nonsurgical treatments should be considered as
first-line therapy. Use of estrogen creams, dilation, and
focused voiding treatments may obviate the need for surgery.
Furthermore, adult women who are having diﬃculty with
sexual performance may find that sex therapy or psychologi-
cal counseling is helpful.
5.6. Transition of Surgical Care from Childhood into Adult-
hood. One of the most challenging aspects of surgical
care for patients with CAH is the transition into adult
care. Neither pediatric urologists/surgeons nor adult urolo-
gists/gynecologists have significant experience with care of
adult women with CAH. It is, therefore, suggested that two
designations be considered for CCC surgical centers. All
designated centers should be capable to care for infants, chil-
dren, adolescents, and young adults to include an age range
from birth to 18 years. Specialty CCC surgery centers with
expertise in treating older individuals (>18 years of age) with
CAH will be further certified as Adult Centers of Excellence
(ACOE) (Table 2). These centers may best be established by
having the pediatric and adult surgeons working together to
develop combined experience to optimize outcomes. CCCs
that are ACOEs should develop expertise in helping adult
women with CAH using nonsurgical and, when necessary,
surgical techniques to improve sexual and reproductive
function. For example, postsurgical vaginal stenosis may be
alleviated by vaginal dilation, which should be attempted
before the more significant intervention of surgical revision
of prior surgery. Also, approaches should be undertaken
to demedicalize management of issues of sexual function
for women with CAH, such as using small commercially
available vibrators instead of medically prescribed rods for
dilation. A sex therapist may be of great importance in
working with postsurgical adult patients. Self-esteem and
self-confidence are critical aspects of long-term overall well-
being for these women.
6. Advocacy and Education
6.1. Definition. Advocacy is defined as the active support
of a cause or course of action. In the context of the CAH
CCC, this means every person who works in the center
advocates for the well-being of people aﬀected with CAH by
both reaching out to the community outside the CCC and
educating those within. In this paper, “aﬀected people” is an
inclusive term that will refer to people living with a diagnosis
of CAH, as well as to other people in their lives who are
also touched by CAH, including parents, siblings, partners,
spouses, friends, and coworkers. Advocacy and education are
fundamental to empowering all of those aﬀected by CAH and
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Table 2: Criteria for defining CCC surgical centers of excellence.
(i) Comprehensive care team including endocrinology, anesthesiology, uroradiology facilities, intensive care unit, ancillary support staﬀ
(ii) Surgeons are fellowship-trained and board-certified (subspecialty certification) in pediatric urology or pediatric surgery
(iii) Training must have included considerable exposure to CAH surgical techniques, with a minimum of 5 CAH feminizing
genitoplasty surgeries.
(iv) Surgical volume must reflect ongoing interest and competence
(v) Surgeons designated as CCC surgeons must have completed at least 10 CAH surgeries as an attending surgeon within the prior eight
years from date of application.
(vi) Peer-reviewed publications related to genital surgery in CAH patients
(vii) Multidisciplinary conference at least once every 3 months
(viii) Outcome measures and submission of data to a national CAH registry
(a) Type(s) of surgical procedure(s), age at operation, complications, and initial surgical outcome 1 year postoperatively
(b) Numbers of operations and complications
(c) Pubertal evaluation for general appearance, void function, and vaginal patency for menses and tampon use
(d) Evaluation at time of desire (or potential) to begin sexual activity to assess adequacy of vaginal caliber for intercourse (self-dilation
versus revision may be needed)
(e) Long-term followup at age 18 or older: the most important followup is assessed from the patient’s point of view, involving detailed
questionnaires (psychosocial, sexual, and functional/anatomical) and interviews by independent assessors. Evaluation for general
appearance, void function, vaginal patency, and clitoral sensitivity should be performed
(f) Data on adult quality of life, sexual functioning, obstetric history, and continence should be collected and assessed to determine the
quality of the surgical techniques used and quality of postsurgical psychological support services and education of patients provided.
improving their quality of life. The foremost goal of advocacy
in the CCCs should be to improve the quality of life of people
aﬀected by CAH, both the individuals themselves and those
with whom they share their lives.
Many families express shock and dismay regarding the
lack of knowledge about CAH on the part of school
employees, local emergency department personnel, and
other healthcare providers. Patients and parents need to
be provided with tools that enable them to be eﬀective
advocates for themselves or their children in these settings.
Clear, concisely written information, provided as pamphlets
or laminated placards, about CAH and response to adrenal
crisis should be available to parents for dissemination to
schools, EMTs, daycare centers, and other relevant settings
(available through CARES Foundation).
6.2. Philosophy and Implementation. The CCC should be
more than just a place where clinicians converge to see
patients. Comprehensive care improves health-related qual-
ity of life for patients with other conditions, and it is likely
that the same improvements will occur for CAH. While
specialists from various disciplines often confer on diﬃcult
cases during the typical course of patient care, the formation
of a multidisciplinary team signifies formal commitment to
principles of professionalism such as communication and
cooperation that underpin eﬀective treatment of the whole
patient [13]. CCCs can createmodels for transparent, honest,
and ethical decision-making with full informed consent
at its core and can help aﬀected people understand and
evaluate potential outcomes, risks, and benefits of various
healthcare decisions through the presentation of information
in a nondirective and nonjudgmental way while defending
the patient’s best interests.
6.3. Education. Advocacy and education intersect in several
ways in the CCC. When team members educate their
peers and colleagues through training and educational
programs, and by conducting and publishing research, they
are advocating for the community of people aﬀected by
CAH by raising awareness and understanding of the disorder
(Table 3). When the team teaches parents and individuals
diagnosed with CAH how to better communicate their needs
with healthcare providers and others, they are teaching
advocacy. Team members who work with support groups
to provide education to aﬀected people about living with
CAH help them to better understand how to manage life
with the disorder, thereby supporting individual advocacy.
The healthcare providers on the CCC team empower aﬀected
people to become advocates for themselves by providing
them with knowledge and strategies to improve their eﬀec-
tiveness. Advocacy through education improves care, creates
trust in the healthcare team, and leads to better overall
communication and healthcare experiences.
6.4. Education of Families and Patients Leading to Empow-
erment. Engaging patients/families as eﬀective partners in
care management and shared decision making is vital to
assuring high quality, appropriate care [13]. Evidence from
studies of patients with other chronic medical conditions
confirms that openness in the sharing of information
is associated with enhanced psychosocial adaptation [36,
37]. With the help and guidance of the CCC, parents
should progress from being “parents only” to “parents
of a child with CAH” and ultimately “parent advocates.”
Parents should be provided with the knowledge, the
words and phrases required to educate their child and
other family members, and tools to proactively deal with
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Table 3: Components of advocacy and education.
(i) Designate one team member to serve as a care coordinator to provide the point of contact.
(ii) Development of uniform, standardized educational materials, and professional training modules for aﬀected people and health care
providers dealing with diﬀerent periods in the life cycle. Such materials would focus on various relevant subjects, using culturally sensitive
terminology and health literacy tools, and would be provided in diﬀerent common languages. Examples of modules include:
(a) the newly diagnosed infant,
(b) the toddler,
(c) the school-aged child,
(d) the teenage girl,
(e) the teenage boy,
(f) the individual in transition from pediatric to adult care,
(g) the adult woman,
(h) the adult man,
(i) special needs of the patient with atypical genital development,
(j) special concerns of the patient with NCAH,
(k) emergency training for families and patients,
(l) preparing for school and child care,
(m) dealing with discrimination in school, sports, or employment situations,
(n) reproduction and fertility,
(o) identifying psychosocial adjustment issues,
(p) obesity, growth, and bone health,
(q) testicular tumors, self-examination, and fertility,
(r) genetic consequences of CAH,
(s) frequently asked questions.
(iii) Development of a timeline for the delivery of health information to aﬀected people and provision of educational materials to aﬀected
people and their families.
(iv) Development and maintenance of a comprehensive library of materials and web-based activities which can include informational
pamphlets and videos, local support group contact information, brochures from support and advocacy organizations, decision pointers,
and information on informed consent, medical privacy, and patient rights.
(v) Promotion of informal contact among aﬀected people of all ages and medical and support staﬀ through scheduling routine
appointments for adults and children with CAH on the same day, with the aim of shared learning (details provided elsewhere). CCC
evaluations are performed in rooms spacious enough to accommodate those who support patients with CAH during appointments.
both medical and psychosocial issues associated with the
condition.
In adults with CAH, CCC should demonstrate sensitivity
to the patient’s experiences with prior treatments and
healthcare professionals, with an emphasis on building trust
in the CCC. At all ages, aﬀected people must be reminded
that CAH is a part of their lives, but should not be defining,
and that not everything about them is attributable to CAH.
CCCs should proactively help aﬀected people synthesize and
interpret information from a variety of sources, including
information and potential misinformation gleaned through
the internet and media.
The CCCs should assist aﬀected people in organizing or
contacting local support groups, coordinating educational
and social gatherings with support group members, and
facilitating team involvement in support group activities.
The CARES Foundation can provide helpful resources,
including educational materials and training programs for
group leaders. These services may provide an eﬀective tool
to assist in forming social support systems shown to buﬀer
the negative eﬀects that these diagnoses may engender, help
new parents master relevant information in their own terms,
and provide strategies and role-playing opportunities for
handling various social situations.
Delivering diagnostic and medical management infor-
mation is a collaborative progressive process, not a single
event, with a variable tempo depending on individual
circumstances. Thus, a flexible individual-based approach
is preferable. During the newborn period, the number of
nonessential staﬀ who interact with the baby and family,
especially virilized female babies, should be limited; how-
ever, for the purposes of training others, strategies such
as technological and audio/visual approaches should be
considered under certain conditions, with sensitive handling
and appropriate deidentification and informed consent.
Providing people aﬀected by CAH with a lexicon of terms
for describing their condition in nonstigmatizing ways may
help them with social skills. Patients and families may seek
help to resolve what, when, how, and with whom to share
information about CAH. Cultural, ethnic, and religious sen-
sitivities must be understood and acknowledged. Although
there is no universally “correct” approach, a discussion
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with the patient and family about the benefits of selective
information sharing, with accompanying strategies, should
oﬀer the individuals and parents considerable psychological
relief [38]. Aﬀected individuals who wish to examine their
personal medical records should be allowed full access to
review their medical history and treatment from infancy to
the present time.
Advocacy and education should be fundamental to
empowering all of those aﬀected by CAH and improving
their quality of life. The major philosophy of comprehensive
care is person/family-centered, holistic, culturally sensitive,
and eﬀective care that considers the medical, emotional,
psychosocial, and financial needs of people aﬀected by CAH.
CCCs should provide patient-centered care through collabo-
rative evaluation andmanagement strategies, shared decision
making, and promotion of medical independence. CCCs
and team members should participate in advocacy outside
the local setting with other centers of excellence through
education, research, and outreach. CCC should provide
specific strategies to educate aﬀected people throughout the
life cycle.
7. Training, Research, and Registry
7.1. Training. Improving the quality of care provided to
the adult CAH patient and education of internal medicine
endocrinologists and other team healthcare providers by the
pediatric endocrinology team is essential. Pediatric endocri-
nologists have more experience with CAH for a variety
of reasons, most predominantly because of the consistency
and coordination of care for genetic disorders that occurs
during childhood. Through the coordination of care among
the pediatric, internal medicine, and subspecialty practices
during transition, and regular, meaningful communication
about the needs of the individual patient and how to best
address those needs, the internal medicine endocrinologists
and subspecialty healthcare providers will be better trained
to care for those with CAH. Thus, the training of the
physicians, nurses, and other healthcare providers who
deliver or will deliver health care to individuals with CAH
throughout the life cycle should be central to the develop-
ment and implementation of CCCs [39]. Centers should
also encourage research and teaching of behavioral health
issues and counseling techniques to increase the number of
behavioral health providers skilled in the care of patients
with CAH. Care for individuals with CAH begins from
the preconception period and encompasses birth, infancy,
puberty and adolescence, and adulthood.
Graduate medical education (GME) programs will ben-
efit from having proficiency-based goals with opportunities
for didactic lectures, informal discussion, and supervised
clinical experiences [40]. The specific goals should be
tailored to the particular needs of the trainees. Mod-
eling on the Accreditation Council for Graduate Medi-
cal Education (ACGME), specific competencies should be
developed for patient care, medical knowledge, practice-
based learning, professionalism, systems-based practice, and
interpersonal and communication skills. Clinical rotations
in pediatric endocrinology for internal medicine endocri-
nologists, reproductive endocrinologists, behavioral health
professionals, and other subspecialists during fellowship will
increase the exposure of these trainees to children and
families with CAH. Faculty mentoring, evaluations, and con-
structive feedback are essential. In today’s world, intermit-
tent and recurring conflicts between academic achievement
(productivity) and family life are almost inevitable. Thus,
training should also involve teaching trainees how to balance
professional duties with commitments to partners, children,
and other family members. For the trainee, having role
models and mentors can guide and help them to acquire the
skills for professional and personal success.
To demonstrate competency in these areas, trainees
should analyze past and current clinical management,
review the current scientific literature, apply knowledge
of study design and statistical analysis, and appropriately
utilize information technology. Trainees should demonstrate
a commitment to ethical principles pertaining to clinical
care. Trainees must respect the confidentiality of patient
information, understand the elements of informed consent,
approach to human (clinical) research, and have current
knowledge regarding business/insurance practices. Improv-
ing communication and leadership skills and training in
newer technology, such as the Electronic Medical Record,
should facilitate interaction and advocacy for patients and
their families. Respect, compassion, integrity, sensitivity to
cultural diversity, and knowledge of the healthcare systems
are essential. Tracking outcomes of training will be essential
for quality improvement of the educational process.
In addition to the intellectual aspects of medical knowl-
edge, proficiency in the appropriate technical skills and
informed decision-making abilities are important for the
adept healthcare professional. Having a child with a chronic
disorder, especially one aﬀecting genital diﬀerentiation, has
the potential to generate much emotional distress and can
result in misunderstanding and miscommunication among
family members [41]. This uneasiness may impact negatively
on intrafamilial interactions and on relationships with
healthcare professionals. Healthcare professionals need to be
comfortable talking with patients and families about CAH
and need to be prepared to discuss concerns related to
gender identity and sexual function. Skillful interaction with
the parents can be important to help them adapt to the
demands of having a child with a chronic disorder. Through
observation and supervised interactions, healthcare trainees
should become proficient in the skills to interact with
people from diﬀerent cultural, ethnic, and socioeconomic
backgrounds. Trainees should learn how to educate the
patient and family members using age-appropriate language
and information. Knowledge of family-centered strategies for
clinical care and communication will be beneficial.
Each CCC should maintain regularly scheduled confer-
ences. Conferences should include case discussions involving
all relevant members of the care team, topic reviews, and
research updates, as well as didactic lectures for trainees
and consumers (Table 4). Interdepartmental meetings that
focus on the needs of the adult and transitioning patients are
encouraged and should improve adult care. More frequent
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Table 4: Potential curriculum and lecture topics.
(i) Newborn screening.
(ii) Sexual diﬀerentiation.
(iii) Management of the newborn.
(iv) Treatment options and surgical management of the virilized
female.
(v) Management considerations for diﬀerent age groups.
(vi) Information for school and sports.
(vii) Treatment of acute adrenal insuﬃciency including
information for emergency medical services (EMS).
(viii) Reproductive issues and concerns.
(ix) Transition to internal medicine care providers.
(x) Preconception counseling and prenatal diagnosis.
(xi) Diagnosis and molecular genetics of CAH.
(xii) Pharmacology of hormone replacement (glucocorticoids
and mineralocorticoid).
(xiii) Coordination of care—working as a team.
(xiv) Adrenal physiology and pathophysiology
(xv) Steroid biosynthesis
meetings or ad hoc meetings may be appropriate for some
centers or be necessary to discuss specific clinical situations.
The CCC is encouraged to oﬀer education in CAH, either
with the distribution of literature or delivery of lectures, such
as grand rounds, at community hospitals. Conferences for
patients and families are encouraged.
7.2. Research and Registry. CCCs should participate in coor-
dinated, multicenter, and multidisciplinary studies designed
to evaluate quality of life throughout the life cycle. These
studies should foster better understanding of the disorder
within and beyond the CCC, which should improve care and
informed decision making for aﬀected individuals and their
families. A nationwide patient registry contributed to and/or
maintained by CCCs will facilitate accumulation of data with
adequate statistical power to discriminate among outcomes
for aﬀected individuals and their families. By publishing such
research, the CCCs can educate their colleagues, aﬀected
people, the medical community at large, and the general
public. Benefits of research via a registry should lead to teams
of interdisciplinary experts to investigate research topics such
as improved therapeutic options, optimizing transitions,
and evaluation regarding comorbid conditions (obesity,
insulin resistance, and osteoporosis). Outcome studies and
interviews with adult patients should provide insight into
the management of long-term psychosocial implications of
CAH.
Disease or patient registries provide a valuable mech-
anism to track the health of individuals with specific rare
disorders. Registries can capture, manage, and provide
information to assist with the care of aﬀected individuals by
facilitating systematic research. Data contained within the
registry must be secure and access to the data should be
limited. The registry should have IRB approval as a longi-
tudinal observational study. Consistency of the information
contained within the registry will provide greater numbers of
patients for analysis of outcome variables and other potential
research areas. Registries currently exist for a number of
disorders such as cystic fibrosis (http://www.cﬀ.org/), rare
autoinflammatory diseases (http://www.esid.org/), spinal
muscular atrophy (http://smaregistry.iu.edu/), and cancer
(http://www.cdc.gov/cancer/npcr/about.htm). This gather-
ing of consistent and accurate information in one location
is critical for patient care, research purposes, and, ulti-
mately, for treatment. The eﬀectiveness of patient education
materials should be assessed. Research protocols should
be publicized through a registry website. Health trends
and pharmacological treatments should be reviewed and
analyzed. Outcome data acquired through registries should
be analyzed and used to improve both individual patient care
and the healthcare delivery system [1].
Since state NBSs report all confirmed cases to the
National Newborn Screening Information System (NNSIS),
interconnectivity with this system would be beneficial. The
recent expansion of NBS programs to provide long-term
followup should provide an opportunity to develop registries
for the life span of patients [42]. The US Secretary of Health
and Human Services’ Advisory Committee on Heritable
Disorders in Newborns and Children has stated that long-
term followup is beneficial for quality assurance, evidence-
based care, care coordination through a medical home
including transition to adult care services, and acquisition
of new knowledge [40]. Consequently, CCCs should work
with the Newborn Screening Translational Research Network
(NBSTRN) to maximize information capture and analysis.
8. Implementation
In addition to the challenges discussed above, finan-
cial support for CCCs is a major hurdle to overcome.
Potential mechanisms for financial support include third
party reimbursement for services provided, research grants
(NIH, private foundations, nonprofit organizations such
as CARES, endocrine societies, and newborn screening
agencies), and/or donations. Families may need to pay a fee
based on their income. The goal of this 1.5 day meeting was
discussion of the components necessary for the ideal CCC.
The next phase will be the implementation of CCCs, which
will include minimum criteria, accreditation, and review.
An important first step will be developing mechanisms to
finance the CCCs. These discussions will benefit from a sep-
arate conference, which includes participants knowledgeable
regarding health care policy and reimbursement [43].
9. Conclusion
The essence of a CCC is patient-centered eﬃcient coordina-
tion of care among multiple healthcare providers extending
from diagnosis through all stages of growth and devel-
opment. Personalized, family-centered, holistic, culturally
sensitive, and eﬀective care should create the foundation
for a CCC for patients and families aﬀected with CAH.
Comprehensive care should consider the medical, emotional,
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psychosocial, and financial needs of patients and their fami-
lies throughout the life span. Internal medicine and pediatric
physicians, nurses, behavioral/psychosocial health providers,
nutritionists, genetic counselors, care coordinators, and
others should collaborate as a team to create a comprehensive
plan for patients with CAH. The individual, and his or her
long-term health outcomes and quality of life, in addition
to his or her clinical data, should be the central focus of the
CAH CCC. Collaboration, cooperation, teamwork, clinical
investigation, and training must be important components
of a CCC.
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